Filing Flows › Novo Nordisk A S (NVO) › Takeover & LBO
Is Novo Nordisk A S (NVO) a takeover target?
A leveraged buyout at today's price plus 30% ($54.83 a share) would return about 30% a year to a private-equity buyer over 5 years; the most a buyer could pay for a 20% return is $69.15 a share (64% against today's $42.18). At $241.8B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect.
The buyout, step by step
| Entry | Amount | How |
|---|---|---|
| Offer price a share | $54.83 | today's $42.18 plus 30% |
| × shares | 4,409.2 million | |
| = Equity value | $241.8B | |
| + Debt refinanced | $0 | |
| − Cash | $0 | |
| = Enterprise value | $241.8B | 1.7× EBITDA of $142.3B |
| Fees | $4.8B | 2% of the price |
| New debt | $157.2B | 1.1× EBITDA at 7.65% a year; the limit that binds: 65% of the price |
| Buyer's own money | $89.5B | 36% of the cost |
5 years under the buyer
| Year | Revenue | EBITDA | Interest | Free cash flow | Debt left |
|---|---|---|---|---|---|
| Year 1 | $318.3B | $146.6B | $12.0B | $46.0B | $111.2B |
| Year 2 | $327.9B | $151.0B | $8.5B | $50.4B | $60.8B |
| Year 3 | $337.7B | $155.5B | $4.6B | $55.1B | $5.6B |
| Year 4 | $347.9B | $160.2B | $431M | $60.2B | $0 |
| Year 5 | $358.3B | $165.0B | $0 | $62.4B | $0 |
The exit and the buyer's return
| Exit | Amount | |
|---|---|---|
| Exit multiple | 1.3× EBITDA | today's trading multiple, before any premium |
| Enterprise value at exit | $215.6B | |
| − Debt left | $0 | |
| + Cash built up | $116.9B | |
| = Buyer's equity | $332.5B | |
| Money multiple | 3.72× | on $89.5B put in |
| Buyer's yearly return (IRR) | 30.0% |
Price against return
What the buyer makes at other premiums over today's $42.18; the IRR reaches 20% at $69.15 a share.
| Premium | Price a share | Buyer's IRR |
|---|---|---|
| 10% | $46.40 | 36.7% |
| 20% | $50.62 | 33.3% |
| 30% | $54.83 | 30.0% |
| 40% | $59.05 | 26.9% |
| 50% | $63.27 | 24.0% |
The figures used
| Figure | Amount | |
|---|---|---|
| Revenue, last 12 months | $309.1B | |
| EBITDA, last 12 months | $142.3B | 46.1% of revenue |
| Depreciation and amortization | $14.7B | |
| Capital spending | $60.1B | |
| Debt | $0 | |
| Cash | $0 | |
| Share price | $42.18 | on Nov 6, 2026 |
Fixed rules, the same as the interactive view's starting point: the shares are bought at today's price plus 30%, the company's debt is refinanced and fees take 2%. New debt is the least of 5.5× EBITDA, 65% of the price and the amount whose interest EBITDA covers 2 times, at 7.65% a year (SOFR 3.89% plus the high-yield B spread 3.26% plus 0.5%, rates of Oct 15, 2026). Revenue grows 3.0% in the first year — the company's own rate, held between −3% and +8% — fading to 3% by year 5; the EBITDA margin, depreciation and capital spending stay at today's share of revenue; working capital takes 10% of each year's added revenue; tax is 22% of profit after interest. Every dollar of free cash flow repays debt. After 5 years the buyer sells at today's multiple of EBITDA.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Novo Nordisk A S would cost about $56.94 a share, $251.1B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $51.46 | $226.9B |
| Median | 35% | $56.94 | $251.1B |
| High end (a quarter paid more) | 45% | $61.16 | $269.7B |
Novo Nordisk A S' latest quarter
Novo Nordisk A S, FY2025: revenue $309.1B (+6% year over year), operating margin 41.3%, net earnings $102.4B, operating cash flow $119.1B. The chart follows the revenue to costs, profit and cash.
Questions
Is Novo Nordisk A S being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Novo Nordisk A S?
A leveraged buyout at today's price plus 30% ($54.83 a share) would return about 30% a year to a private-equity buyer over 5 years; the most a buyer could pay for a 20% return is $69.15 a share (64% against today's $42.18). At $241.8B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect.
What would a takeover of Novo Nordisk A S cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Novo Nordisk A S would cost about $56.94 a share, $251.1B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.